Elena Elimova, MD

Elena Elimova, MD, discusses data from a HERIZON-GEA-01 PD-L1 subgroup analysis in HER2-positive gastroesophageal adenocarcinoma.

Frontline HER2-positive gastric cancer trials test T-DXd combos and TIGIT/PD-L1 bispecifics, aiming to improve survival beyond trastuzumab.

Experts weigh T‑DXd as second-line HER2+ gastric cancer therapy, stressing rebiopsy/ctDNA and vigilant pneumonitis risk.

Experts weigh T‑DXd for HER2+ gastric cancer after prior therapy, stressing rebiopsy or ctDNA confirmation and vigilant pneumonitis monitoring.

Clinicians share real-world tips to prevent and manage zanidatamab-related diarrhea, using early loperamide, patient counseling, follow-up calls, and supportive care.

Experts weigh using triplet immunotherapy plus chemo for PD‑L1–negative patients, balancing survival gains, side effects, and FDA approval in first-line care.

New trial updates tease stronger survival with zanidatumab combos; two analyses ahead may clarify OS, biomarkers, and tislelizumab’s added value.

New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.

HORIZON GEA 01 shows zanidatamab regimens significantly improve survival in HER2-positive gastric, esophageal, and GEJ cancer, while PD-L1 testing differences raise key questions for treatment choice.

Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.

Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.

Experts unpack zanidatamab’s dual HER2 binding, why JACOB nearly succeeds, and what standout gastric and biliary cancer responses mean next.

Clinicians explain zanidatamab’s action and HORIZON-GEA-01

Rapid readout: Phase III data show zanidatamab with chemo ± PD-1 inhibitor extends PFS and OS in HER2+ metastatic gastroesophageal cancer.

Elena Elimova, MD, discusses efficacy data for zanidatamab in HER2-positive gastroesophageal adenocarcinoma from HERIZON-GEA-01.

Elena Elimova, MD, discusses the efficacy of zanidatamab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma.